Delayed
Bombay S.E.
06:00:57 2024-07-15 am EDT
|
5-day change
|
1st Jan Change
|
95.45
INR
|
+1.01%
|
|
+1.01%
|
+146.01%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
43.55
|
52.26
|
48.74
|
69.6
|
427.7
|
255.4
|
Enterprise Value (EV)
1 |
137.8
|
168.3
|
166.9
|
200.7
|
557.6
|
411.4
|
P/E ratio
|
-3.02
x
|
-3.29
x
|
-32.2
x
|
6.67
x
|
13.9
x
|
7.63
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.94
x
|
1.09
x
|
0.22
x
|
0.22
x
|
1.23
x
|
0.66
x
|
EV / Revenue
|
2.99
x
|
3.51
x
|
0.77
x
|
0.63
x
|
1.61
x
|
1.07
x
|
EV / EBITDA
|
-30.1
x
|
-21.4
x
|
14.5
x
|
4.93
x
|
11
x
|
7.33
x
|
EV / FCF
|
-
|
-10,113,878
x
|
-4,878,634
x
|
-5,932,561
x
|
-63,614,681
x
|
-12,120,391
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
-0.68
x
|
-0.66
x
|
-19
x
|
14.1
x
|
10.3
x
|
3.41
x
|
Nbr of stocks (in thousands)
|
5,040
|
5,040
|
5,040
|
5,040
|
10,938
|
10,938
|
Reference price
2 |
8.640
|
10.37
|
9.670
|
13.81
|
39.10
|
23.35
|
Announcement Date
|
9/4/19
|
9/4/19
|
9/4/21
|
9/4/21
|
9/3/22
|
9/2/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
46.17
|
47.97
|
218
|
318.1
|
346.9
|
386.2
|
EBITDA
1 |
-4.586
|
-7.855
|
11.55
|
40.69
|
50.88
|
56.12
|
EBIT
1 |
-7.71
|
-10.97
|
8.374
|
33.61
|
43.67
|
48.6
|
Operating Margin
|
-16.7%
|
-22.86%
|
3.84%
|
10.57%
|
12.59%
|
12.58%
|
Earnings before Tax (EBT)
1 |
-14.25
|
-15.92
|
0.1684
|
26.19
|
37.27
|
37.72
|
Net income
1 |
-14.25
|
-15.92
|
-2.889
|
22.99
|
30.13
|
33.3
|
Net margin
|
-30.87%
|
-33.19%
|
-1.33%
|
7.23%
|
8.68%
|
8.62%
|
EPS
2 |
-2.860
|
-3.150
|
-0.3000
|
2.070
|
2.820
|
3.060
|
Free Cash Flow
|
-
|
-16.64
|
-34.21
|
-33.84
|
-8.765
|
-33.95
|
FCF margin
|
-
|
-34.69%
|
-15.7%
|
-10.64%
|
-2.53%
|
-8.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/4/19
|
9/4/19
|
9/4/21
|
9/4/21
|
9/3/22
|
9/2/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
94.3
|
116
|
118
|
131
|
130
|
156
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-20.56
x
|
-14.77
x
|
10.23
x
|
3.223
x
|
2.554
x
|
2.781
x
|
Free Cash Flow
|
-
|
-16.6
|
-34.2
|
-33.8
|
-8.77
|
-33.9
|
ROE (net income / shareholders' equity)
|
-
|
22.4%
|
6.36%
|
-3,953%
|
115%
|
57.2%
|
ROA (Net income/ Total Assets)
|
-
|
-13.3%
|
5.6%
|
13.9%
|
15.1%
|
13.4%
|
Assets
1 |
-
|
119.5
|
-51.6
|
165.3
|
199.9
|
248.8
|
Book Value Per Share
2 |
-12.70
|
-15.70
|
-0.5100
|
0.9800
|
3.790
|
6.850
|
Cash Flow per Share
2 |
0.0100
|
0.0100
|
0.0200
|
0.0100
|
0.0200
|
0.0100
|
Capex
1 |
0.48
|
3.26
|
2.18
|
38.9
|
12.1
|
17.3
|
Capex / Sales
|
1.05%
|
6.79%
|
1%
|
12.23%
|
3.49%
|
4.47%
|
Announcement Date
|
9/4/19
|
9/4/19
|
9/4/21
|
9/4/21
|
9/3/22
|
9/2/23
|
|
1st Jan change
|
Capi.
|
---|
| +146.01% | 12.49M | | +28.34% | 2.68B | | +28.15% | 2.53B | | -45.34% | 2.34B | | +36.67% | 2.11B | | -31.46% | 2.05B | | -24.50% | 1.59B | | +14.55% | 1.46B | | +36.22% | 1.38B | | +18.21% | 1.26B |
Medical Supplies
|